Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003167 · ClinicalTrials.gov registry record · Phase 1
Gene Therapy in Treating Patients With Advanced Bladder Cancer
A Phase 1 study of Recurrent Bladder Cancer and Transitional Cell Carcinoma of the Bladder, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT00003167: Completed Phase 1 study of Recurrent Bladder Cancer and Transitional Cell Carcinoma of the Bladder, sponsored by National Cancer Institute (NCI).
NCT00003167 is a Phase 1 study of Recurrent Bladder Cancer and Transitional Cell Carcinoma of the Bladder that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 24 participants, below the 102-participant average among 5 other Recurrent Bladder Cancer trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003167, a Phase 1 study of Recurrent Bladder Cancer and Transitional Cell Carcinoma of the Bladder, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
Phase I trial to study the effectiveness of gene therapy in treating patients with advanced bladder cancer. Inserting the p53 gene into a person's bladder cancer cells may improve the body's ability to fight cancer
Conditions Studied
Interventions
- BIOLOGICAL Ad5CMV-p53 gene
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 1998-05 |
| Phase | Phase 1 |
What the finished NCT00003167 record still lists
NCT00003167 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 102-participant average among 5 other Recurrent Bladder Cancer trials with a reported enrollment target (76% lower).
The record links to 6 conditions, with Recurrent Bladder Cancer appearing as the primary indexed condition, and to 1 intervention - of which Ad5CMV-p53 gene is the first listed.
NCT00003167 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00003167 about?
NCT00003167 is a clinical study titled "Gene Therapy in Treating Patients With Advanced Bladder Cancer". Phase I trial to study the effectiveness of gene therapy in treating patients with advanced bladder cancer. Inserting the p53 gene into a person's bladder cancer cells may improve the body's ability to fight cancer
What is the current status of trial NCT00003167?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 1998-05.
What conditions does trial NCT00003167 study?
This clinical trial studies the following conditions: Recurrent Bladder Cancer, Transitional Cell Carcinoma of the Bladder, Stage IV Bladder Cancer, Stage III Bladder Cancer, Stage I Bladder Cancer.
What interventions are being tested in trial NCT00003167?
The interventions under investigation include: Ad5CMV-p53 gene (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003167?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003167 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Decitabine in Treating Patients With Advanced Solid Tumors
COMPLETED · Phase 1
-
Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2
RECRUITING
-
A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Pazopanib in Treating Patients With Metastatic Urothelial Cancer
COMPLETED · Phase 2
-
Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia